FeesSafety
Pluang+

Updated Phase 1 data show Pyxis Oncology's MICVO drug effective in advanced head and neck cancer with 39% response rate

Company Fundamentals
19 Nov 2026, 01:01 WIB
GlobeNewsWire
View Source
Bullish
Updated Phase 1 data show Pyxis Oncology's MICVO drug effective in advanced head and neck cancer with 39% response rate

Pyxis Oncology announced updated Phase 1 trial results for its drug micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The data showed a 39% confirmed objective response rate, median progression-free survival of 6.7 months, and median duration of response of 9.2 months, with consistent activity across patient subgroups and a manageable safety profile. These promising results support advancing MICVO into a global Phase 3 trial planned for mid-2027. The findings were presented at the EORTC-NCI-AACR Symposium and underscore MICVO's potential as a new treatment option for patients with limited therapies after platinum chemotherapy and immunotherapy.

Pyxis Oncology's updated Phase 1 data on MICVO provides context for health sector trends. As of Nov 19, 2026 05:11 WIB, 51 of 150 health stocks rose while 98 fell on Pluang. Notable movers include FLNA up 20.63% with 100% sell orders, HUM down 13.36% with 99% sell orders, and UNH down 10.55% with 88% sell orders.

More News

Neuronetics grants inducement RSUs to a new employee under Nasdaq rules

Neuronetics grants inducement RSUs to a new employee under Nasdaq rules

Neuronetics, a leader in interventional mental health, awarded 9,000 restricted stock units (RSUs) to Julia Roussel as an inducement for employment, approved under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over three years, contingent on continue...

Company Fundamentals
Neutral
1 hour ago
S&P 500 dips below 200-day average amid regulatory fears and hawkish Fed outlook

S&P 500 dips below 200-day average amid regulatory fears and hawkish Fed outlook

The S&P 500 fell 0.24%, slipping below its key 200-day moving average, driven by heavy losses in healthcare stocks due to new Medicare audit proposals. The Dow dropped 1.11%, while the Nasdaq rose 0.42% supported by tech and retail gains. The Federal...

Bearish
1 hour ago
Cryptocurrency prices fall amid liquidity concerns and Fed policy uncertainty, Bitcoin nears $62,000 lows.

Cryptocurrency prices fall amid liquidity concerns and Fed policy uncertainty, Bitcoin nears $62,000 lows.

Cryptocurrency markets continued their decline on November 18, driven by worsening liquidity and cautious investor sentiment amid uncertainty about Federal Reserve policy. Bitcoin dropped nearly 4% to around $62,386, approaching recent lows, while Et...

Bearish
1 hour ago
Opendoor shares rise 7.63% on new FSBO.com deal and insider buying amid housing market challenges

Opendoor shares rise 7.63% on new FSBO.com deal and insider buying amid housing market challenges

Opendoor Technologies' stock rose 7.63% to $1.27 following a new partnership with FSBO.com and insider buying by a company director, signaling potential recovery. Despite a 12% sales increase to $1 billion in Q3, net losses widened to $218 million, r...

Market News
Bullish
1 hour ago
Invesco QQQ Trust dips 14% from record but could rise 36% by 2030 on earnings growth.

Invesco QQQ Trust dips 14% from record but could rise 36% by 2030 on earnings growth.

The Invesco QQQ Trust, tracking the Nasdaq-100, hit a record $759.66 in October but has since fallen about 14% to around $654. Despite this drop, it remains up 6% for 2026. The fund's future looks promising with an expected rise to $890 by 2030, driv...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App